Latest VRTX news

Vertex Posts Positive Phase II Data on Kidney Disease Drug

Zacks Investment Research · Wed, 23 Sep 2026 13:11:07 -0400

VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.

Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug

Benzinga · Tue, 22 Sep 2026 13:55:42 -0400

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday reported data from its Phase 2b AMPLIFIED trial evaluating inaxaplin in individuals with APOL1-mediated kidney disease (AMKD).

The Surprise That Sent Vertex — And Its Chief Rival — Soaring

Investors Business Daily · Tue, 22 Sep 2026 13:39:22 -0400

Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs.

Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

Barrons · Tue, 22 Sep 2026 12:46:00 -0400

Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Zacks Investment Research · Tue, 22 Sep 2026 10:01:12 -0400

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

Business Wire · Tue, 22 Sep 2026 08:00:00 -0400

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes. In this study, inaxaplin was evaluated as a 45 mg once-daily dose on top of optimized standard of care. Forty-one people were enrolled and dosed in two cohorts: 1) people with AMKD with modest proteinuria (UACR ≥0.1 g/g to.

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why

Zacks Investment Research · Fri, 18 Sep 2026 18:50:57 -0400

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $508.34, signifying a -1.55% move from its prior day's close.

Market information is provided for research and visualization and is not investment advice.